Renaissance Technologies LLC Has $109.49 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Renaissance Technologies LLC lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 12.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,025,868 shares of the specialty pharmaceutical company's stock after selling 139,700 shares during the quarter. Renaissance Technologies LLC owned approximately 1.63% of Jazz Pharmaceuticals worth $109,491,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in JAZZ. Private Advisor Group LLC increased its position in shares of Jazz Pharmaceuticals by 49.2% during the 4th quarter. Private Advisor Group LLC now owns 2,967 shares of the specialty pharmaceutical company's stock worth $365,000 after purchasing an additional 979 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its position in shares of Jazz Pharmaceuticals by 40.4% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 7,601 shares of the specialty pharmaceutical company's stock worth $935,000 after purchasing an additional 2,186 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of Jazz Pharmaceuticals by 48.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 10,949 shares of the specialty pharmaceutical company's stock worth $1,347,000 after purchasing an additional 3,591 shares in the last quarter. Panagora Asset Management Inc. grew its holdings in Jazz Pharmaceuticals by 42.7% during the 4th quarter. Panagora Asset Management Inc. now owns 18,058 shares of the specialty pharmaceutical company's stock worth $2,221,000 after acquiring an additional 5,407 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Jazz Pharmaceuticals during the 4th quarter worth about $380,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Up 1.8 %

Jazz Pharmaceuticals stock traded up $1.98 during midday trading on Tuesday, hitting $111.55. 714,552 shares of the stock were exchanged, compared to its average volume of 687,361. The company has a fifty day simple moving average of $110.43 and a two-hundred day simple moving average of $111.15. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $137.38. The stock has a market capitalization of $7.03 billion, a PE ratio of 23.00, a P/E/G ratio of 1.31 and a beta of 0.57. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of research analyst reports. The Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a "buy" rating and a $169.00 price objective on the stock. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a report on Monday, August 19th. HC Wainwright reissued a "buy" rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Needham & Company LLC reissued a "buy" rating and set a $205.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Finally, Morgan Stanley decreased their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an "equal weight" rating on the stock in a report on Friday, July 12th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $173.07.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm's stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.20% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.